Status In progress
Process STA
ID number 761
Referral date 01 March 2015

Provisional Schedule

Expected publication 07 February 2018

Project Team

Project lead Jeremy Powell

Email enquiries


Companies sponsors Grunenthal (NB Grunenthal have taken on commercialization responsibility for lesinurad from AstraZeneca)
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups UK Gout Society
Professional groups British Society for Rheumatology
  Primary Care Rheumatology Society
  Royal College of Pathologists
  Royal College of Physicians


Comparator companies A. Menarini Pharma (febuxostat) (not participating)
General commentators Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland


Key events during the development of the guidance:

Date Update
18 December 2017 - 12 January 2018 Final appraisal determination
18 October 2017 Committee meeting: 3
03 July 2017 The company (GrĂ¼nenthal) have informed NICE that it intends to undertake additional work and submit new evidence. NICE has agreed that this additional evidence is relevant for the appraisal. Therefore, the committee meeting for this topic will be delayed, and will no longer take place in July 2017. We will provide an update on the future timelines as soon as we can.
09 June 2017 - 30 June 2017 Appraisal consultation: 2
20 April 2017 Committee meeting: 2
03 August 2016 - 24 August 2016 Appraisal consultation: 1
15 August 2016 The company which has the rights to lesinurad has changed during the course of this appraisal from AstraZeneca to GrĂ¼nenthal. As a result, NICE has agreed to reschedule the second committee meeting for this topic to enable to company to be adequately prepared. The rescheduled committee date is yet to be confirmed.
06 July 2016 Committee meeting: 1
12 February 2016 Invitation to participate

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance